(AOF) – GeNeuro announces today that the Independent Data Monitoring Committee of the trial evaluating its product temelimab in Long Covid has recommended “continuing the trial without any modification”. The biotech, whose objective is to stop the causal factors in the progression of neurodegenerative and autoimmune diseases, specifies that the study evaluates the effectiveness and safety of treatment with temelimab in terms of improvement in measures of fatigue and of cognitive disorders and that the results are expected in June 2024.
The “Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-Covid 19 or PASC Syndrome” trial is a randomized, placebo-controlled, biomarker-based, phase 2 clinical trial evaluating the treatment effect of temelimab on the clinical course of these symptoms.
The trial recruited 203 patients from 14 clinical centers in Switzerland, Spain and Italy, all affected by post-COVID neurological syndromes, and who were diagnosed positive for the presence of W-ENV in their blood. W-ENV is suspected of playing a key role in the persistence of inflammation and neurological symptoms affecting these patients, and temelimab is a highly specific anti-W-ENV antibody capable of neutralizing W-ENV.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
